- Home
- JSPR vs REAL Comparison
JSPR vs REAL Comparison
Compare JSPR & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JSPR | REAL |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1M | 1.9B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | JSPR | REAL |
|---|---|---|
| Price | $0.83 | $9.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $15.50 | ★ $17.00 |
| AVG Volume (30 Days) | 272.2K | ★ 3.9M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.55 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $692,845,000.00 |
| Revenue This Year | N/A | $14.30 |
| Revenue Next Year | N/A | $10.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.38 |
| 52 Week Low | $0.62 | $4.71 |
| 52 Week High | $7.19 | $17.39 |
Technical Indicators
Market Signals| Indicator | JSPR | REAL |
|---|---|---|
| Relative Strength Index (RSI) | 40.19 | 34.32 |
| Support Level | $0.81 | $8.05 |
| Resistance Level | $1.03 | $11.48 |
| Average True Range (ATR) | 0.08 | 0.71 |
| MACD | 0.00 | -0.41 |
| Stochastic Oscillator | 12.81 | 2.80 |
Price Performance
Historical ComparisonAbout JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.